Castilla L H, Couch F J, Erdos M R, Hoskins K F, Calzone K, Garber J E, Boyd J, Lubin M B, Deshano M L, Brody L C
National Center for Human Genome Research, National Institutes of Health, Bethesda, Maryland 20892.
Nat Genet. 1994 Dec;8(4):387-91. doi: 10.1038/ng1294-387.
We analysed 50 probands with a family history of breast and/or ovarian cancer for germline mutations in the coding region of the BRCA1 candidate gene, using single-strand conformation polymorphism (SSCP) analysis on PCR-amplified genomic DNA. A total of eight putative disease-causing alterations were identified: four of these are frameshifts and two are nonsense mutations. In addition, we found two missense mutations, one of which changes the final cysteine of the BRCA1 zinc finger motif to glycine. These data are consistent with a tumour suppressor model, and support the notion that this candidate gene is in fact BRCA1. The heterogeneity of mutations, coupled with the large size of the gene, indicates that clinical application of BRCA1 mutation testing will be technically challenging.
我们对50名有乳腺癌和/或卵巢癌家族史的先证者进行了分析,以检测BRCA1候选基因编码区的种系突变,采用对聚合酶链反应(PCR)扩增的基因组DNA进行单链构象多态性(SSCP)分析的方法。共鉴定出8个推定的致病改变:其中4个是移码突变,2个是无义突变。此外,我们还发现了2个错义突变,其中1个将BRCA1锌指基序的最后一个半胱氨酸变为甘氨酸。这些数据与肿瘤抑制模型一致,并支持该候选基因实际上就是BRCA1这一观点。突变的异质性,再加上该基因的大尺寸,表明BRCA1突变检测的临床应用在技术上具有挑战性。